Physician profile

Danielle Johnson

Family · Binghamton, NY

NPI 1215592878

$519.04

in general payments reported to CMS, 2019-2025

4 companies · $64.93 in 2025

The $64.93 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$419.79

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $466.93 2022-2025 Wegovy, Ozempic
Biohaven Pharmaceuticals, INC. $20.97 2021
Phathom Pharmaceuticals, INC. $17.41 2024 Voquezna
Glaxosmithkline, LLC. $13.73 2024 Shingrix

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Danielle Johnson

$519.04

in general payments reported 2019-2025

Years
2021-2025
Top company
Novo Nordisk INC
Context
The $64.93 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).

https://glasscript.com/doctor/10429284/danielle-johnson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.